Manufacturer with High Purity and Stable Quality
Commercial Supply Imatinib Mesylate (CAS: 220127-57-1) and Related Intermediates:
Imatinib Mesylate (alpha form) CAS: 220127-57-1
N-(2-Methyl-5-nitrophenyl)-4-(pyridin-3-yl)pyrimidin-2-amine CAS: 152460-09-8
N-(5-Amino-2-methylphenyl)-4-(3-pyridyl)-2-pyrimidinea CAS: 152460-10-1
4-[(4-Methylpiperazin-1-yl)methyl]benzoic acid dihydrochloride CAS: 106261-49-8
| Chemical Name | Imatinib Mesylate (alpha form) |
| Synonyms | STI571 Mesylate; CGP-57148B; Imatinib Methanesulfonate |
| CAS Number | 220127-57-1 |
| CAT Number | RF-API19 |
| Stock Status | In Stock, Production Scale Up to Tons |
| Molecular Formula | C30H35N7O4S |
| Molecular Weight | 589.71 |
| Brand | Ruifu Chemical |
| Item | Specifications |
| Appearance | White to Off-White Crystalline Powder |
| Solubility | Easy to dissolve in the water |
| HPLC Identification | Sample spectrum main peak retention time conforms with that |
| IR Identification | Infrared absorption spectrum of sample conforms with reference sample |
| Melting Point | 214.0~222.0℃ |
| Loss on Drying | ≤0.50% |
| Residue on Ignition | ≤0.10% |
| Heavy Metals | ≤20ppm |
| Related Substances | (1) Impurity G: NMT 0.3% |
| (2) Impurity B: NMT 0.3% | |
| (3) Impurity C: NMT 0.3% | |
| (4) Impurity D: NMT 0.3% | |
| (5) Impurity A: NMT 0.3% | |
| (6) Impurity H: NMT 0.3% | |
| (7) Impurity F: NMT 0.3% | |
| (8) Impurity E: NMT 0.3% | |
| (9) The biggest single impurity: NMT0.1% | |
| Residual Solvents | (1) Ethyl Acetate: NMT 5000ppm |
| (2) Methanol: NMT3000ppm | |
| (3) Dichloromethane: NMT 600ppm | |
| (4) Ethanol: NMT 5000ppm | |
| (5) Toluene: NMT 890ppm | |
| (6) Dimethyl Sulfoxide: NMT5000ppm | |
| HPLC Assay | 98.0%~102.0% (C30H35N7SO4 Calculated on the Anhydrous Basis) |
| Test Standard | Enterprise Standard |
| Usage | Active Pharmaceutical Ingredient (API); Ph+CML |
Package: Bottle, Aluminum foil bag, Cardboard drum, 25kg/Drum, or according to customer's requirement.
Storage Condition: Store in sealed containers at cool and dry place; Protect from light, moisture and pest infestation.
Imatinib mesylate is a small molecule that inhibits the c-Abl protein-tyrosine kinase, a kinase specifically important for proliferation of chronic myelogenous leukemia (CML). A translocation event between chromosomes 9 and 22 generates the Philadelphia chromosome, which then produces the Bcr-Abl fusion protein with aberrant kinase activity that promotes rapid cell proliferation. Imatinib mesylate binds up this crucial kinase, halting CML related growth. Imatinib mesylate has further been displayed to inhibit PDGFR and tyrosine kinases associated with c-Kit. Formulations containing Imatinib mesylate have been used in the treatment of various cancers.
Imatinib mesylate is A tyrosine kinase inhibitor. Highly specific for BCR-ABL, the enzyme associated with chronic myelogenous leukemia (CML) and certain forms of acute lymphoblastic leukemia (ALL). It's a potent and selective v-Abl tyrosine kinase inhibitor (IC50 = 38 nM). Also inhibits PDGFR and c-kit. Exhibits selectivity for v-Abl over a panel of other tyrosine and serine/threonine protein kinases. Selectively inhibits PDGF-stimulated growth of v-abl-transformed PB-3 cells and v-sis-transformed BALB/c 3T3 cells in vitro. Exhibits antitumor effects in mice bearing AMuLV or BABL/c 3T3 v-sis cells. Inhibits replication of SARS-CoV and MERS-CoV in vitro (EC50 values are 9.823 and 17.689 μM, respectively).